- ( +41 ) 78 834 6262
- info@tesct.org
- Rainweg 7,CH-3066 Berne-Stettlen.
- English
Dr. Marco Traub has gained considerable experience in a number of research and management and educational roles over the past 20 years. He is the founder of the Trans European Stem Cell Therapy Consortium the (TESCT) in 2005 and acts since as Chair of the TESCT consortium and as EU-Commission Expert in FP7 and the Innovative Medicine Initiative (IMI 1+2) 2018, which is a public private partnership between the European Commission (FP6/FP7/Horizon 2020, Health and Life Sciences) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) and COST framework for Switzerland. While in Switzerland and UK, he specialized in Biotechnology, with focus on PCR technology and peptide synthesis and their GMP production.
In the same period he was Assistant Professor at the Medical School, University of Kansas City, involved in research projects and teaching on neuro anatomy and opiate receptor pharmacology as well as in molecular medicine. His current technical expertise is focused on stem cell isolation and expansion and banking and iPSc with Ge. In addition, he has participated successfully as project co-ordinator in grant applications and (EU) funded projects and has received Exploratory and Research awards from EU-Commission and Swiss Government due to following selected projects: “Development of Ultrasensitive Diagnostic Assays for the Detection of Genetic Disorders, Infections and for Monitoring the Therapeutic Success following Gene Therapy” and “Establishment of novel Targets for Risk Assessment and monitoring of Xenogeneic Infections in the Course of Animal to Human Transplantation”.
He acts as invited speaker and adviser to the World Congress for Freedom of Scientific Research and the “Associazione Luca Coscioni” in cooperation with the Permanent Mission of Italy to the United Nations and International Organizations in Geneva.
Copyright © 2019 TESCT. Developed by BayState InfoTech.
